TAF II p250 Inhibitors
Inhibitors of TAF II p250 form a class of compounds that act through various molecular mechanisms to reduce the activity or expression of this transcriptional coactivator. The inhibition processes are diverse and include the suppression of kinase activity, interference with the transcriptional machinery, obstruction of signaling pathways, and alterations in protein stability or DNA interactions.
The compounds listed operate by disrupting critical nodes in signaling networks such as mTOR, CDKs, and the MAPK/ERK pathway, which are upstream of transcriptional regulation. The inhibition of these kinases by molecules like Rapamycin and Flavopiridol respectively impedes downstream transcriptional events, likely affecting the levels of TAF II p250. Other molecules such as DRB and α-Amanitin directly inhibit the transcription machinery, limiting the transcription of a broad array of genes including that of TAF II p250. Some inhibitors, like Actinomycin D and Mithramycin A, function by binding to DNA and obstructing the transcriptional process. Autophagy inhibitors like Chloroquine and proteasome inhibitors such as MG132 disrupt intracellular degradation pathways, which could lead to an imbalance in cellular protein homeostasis and indirectly affect transcription levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to and inhibits the mechanistic target of rapamycin (mTOR), a key kinase in cell growth and protein synthesis pathways. Inhibition of mTOR can decrease the synthesis of many proteins, potentially including TAF II p250. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
DRB is an adenosine analogue that inhibits cyclin-dependent kinases (CDKs), particularly CDK9, which is part of the positive transcription elongation factor b (P-TEFb) complex. Inhibition of P-TEFb can reduce transcription elongation of various genes, potentially impacting TAF II p250 levels. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is a potent inhibitor of CDKs including CDK9, leading to inhibition of P-TEFb and decreased transcription elongation, which may result in reduced synthesis of proteins like TAF II p250. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide is known to inhibit the transcriptional activity of RNA polymerase II, leading to decreased gene transcription across a broad spectrum of genes, which would likely include TAF II p250. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D intercalates into DNA and prevents the transcriptional elongation by RNA polymerase, thereby potentially reducing the expression of TAF II p250. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin is a potent inhibitor of RNA polymerase II and, at very low concentrations, it can inhibit the mRNA synthesis, which could lead to decreased levels of TAF II p250. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. Since this pathway can regulate the expression of various genes, inhibiting it can reduce the transcriptional levels of TAF II p250. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can affect transcription factor activity and thereby potentially decrease the expression of genes including TAF II p250. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to increased levels of proteins tagged for degradation, potentially disrupting the normal proteostasis and leading to reduced transcription of other proteins, possibly including TAF II p250. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A binds to G-C rich DNA sequences, inhibiting the binding of transcription factors to these regions and potentially downregulating genes, such as TAF II p250, if its promoter contains these sequences. | ||||||